Brief: Clover Announces Positive Phase I Clinical Data For Rsv-Hmpv-Piv3 Combination Vaccines And For Rsv Re-Vaccination In Older Adults
14/10/2025 12:05
Oct 14 (Reuters) - Clover Biopharmaceuticals Ltd 2197.HK: CLOVER ANNOUNCES POSITIVE PHASE I CLINICAL DATA FOR RSV-HMPV-PIV3 COMBINATION VACCINES AND FOR RSV RE-VACCINATION IN OLDER ADULTS CLOVER BIOPHARMACEUTICALS LTD - RSV+HMPV±PIV3 VACCINE CANDIDATES TO ADVANCE TO PHASE II TRIALS IN FIRST HALF OF 2026 CLOVER BIOPHARMACEUTICALS LTD - INCREASES IN NEUTRALIZING ANTIBODIES OBSERVED FOR RSV, HMPV, PIV3 Source text: ID:nPn3kyRhqa Further company coverage: 2197.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clover Biopharmaceuticals
See all newsChina's Clover Biopharma H1 revenue drops sharply, flags going-concern doubt
Brief: Clover Biopharmaceuticals Posts FY Loss Of RMB205.1 MLN
Brief: Clover Announces Positive Phase I Clinical Data For Rsv-Hmpv-Piv3 Combination Vaccines And For Rsv Re-Vaccination In Older Adults
Brief: Clover Biopharmaceuticals Posts H1 Revenue Of RMB3.3 Million
Brief: Clover Biopharmaceuticals Says It Terminates Cooperation With Adimmune